Bibliometric Analysis of The Scientific Literature on Human Papillomavirus Vaccine Clinical Trials: Analysis of PubMed Database

Sushmitha Mohana Murali; Karpagam Senthamarai Kannan; Merrylda Claribel. S

doi:10.55489/njcm.140720232951

Authors

Sushmitha Mohana Murali Independent Health Researcher, Chennai, India https://orcid.org/0000-0001-5457-0402
Karpagam Senthamarai Kannan Independent Health Researcher, Chennai, India
Merrylda Claribel. S Independent Health Researcher, Chennai, India

DOI:

https://doi.org/10.55489/njcm.140720232951

Keywords:

Bibliometrics, human papillomavirus, clinical trials, HPV, HPV vaccine

Abstract

Background: Cervical cancer is the 4^th most common cancer in the world caused by human papillomavirus (HPV). A preventive measure for cervical cancer is immunization with the HPV vaccine. Hence globally many clinical trials on HPV vaccines are being performed to prevent HPV infection. This bibliometric analysis is done to determine the trend of clinical trials on HPV vaccines worldwide over the years.

Methodology: The articles on HPV vaccine clinical trials were extracted from the PubMed database (Mar 1999 – Sept 2022) and the bibliometric data analysis was done using Microsoft Excel.

Result: We extracted 308 articles from the PubMed database and obtained 296 clinical trial articles after removing the non-relevant ones. The majority of the papers were published by institutions in the United States of America (USA) among 39 countries (n=112, 37.8%). Most publications were done by the National Cancer Institute of the USA among 188 institutions worldwide (n=19, 6.4%). The majority of articles were published by more than five authors. Lehtinen M from the Department of Infections and Cancer, German Cancer Research Center has done the most number of publications (n=7). More publications were from the Vaccine journal (n=38). The first three highly cited articles had more than 2000 citations. The years 2015 and 2019 had the highest number of publications (n=25).

Conclusion: We can observe a gradual increase in clinical research on the HPV vaccine over the years that accounts for the reduction in cervical cancer cases.

References

Cervical cancer [Internet]. [cited 2022 Oct 4]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer

II. Complementary data on cervical cancer prevention Figure 2. Estimated coverage of cervical cancer screening in India, by age and study. [cited 2022 Oct 7]; Available from: www.hpvcentre.net

Sousa H, Tavares A, Campos C, Marinho-Dias J, Brito M, Medeiros R, et al. High-Risk human papillomavirus genotype distribution in the Northern region of Portugal: Data from regional cervical cancer screening program. Papillomavirus Res [Internet]. 2019 Dec 1 [cited 2022 Oct 7];8. Available from: /pmc/articles/PMC6702237/ Doi: https://doi.org/10.1016/j.pvr.2019.100179 PMid:31377173 PMCid:PMC6702237

Types of Human Papillomavirus | NYU Langone Health [Internet]. [cited 2022 Oct 7]. Available from: https:// nyulangone.org/conditions/human-papillomavirus/types

Clifford GM, Franceschi S, Keiser O, Schöni-Affolter F, Lise M, Dehler S, et al. Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: A nested case-control study in the Swiss HIV cohort study. Int J cancer [Internet]. 2016 Apr 1 [cited 2022 Oct 7];138(7):1732-40. Doi: https://doi.org/10.1002/ijc.29913 PMid:26537763

Toh ZQ, Kosasih J, Russell FM, Garland SM, Mulholland EK, Licciardi P V. Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infect Drug Resist [Internet]. 2019 Jul 4 [cited 2022 Oct 7];12:1951-67 Doi: https://doi.org/10.2147/IDR.S178381 PMid:31308715 PMCid:PMC6613616

Matys K, Mallary S, Bautista O, Vuocolo S, Manalastas R, Pitisuttithum P, et al. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vaccine Immunol [Internet]. 2012 Jun [cited 2022 Oct 13];19(6):881-5. Doi: https://doi.org/10.1128/CVI.00002-12 PMid:22518014 PMCid:PMC3370453

Guevara AM, Suarez E, Victoria A, Ngan HYS, Hirschberg AL, Fedrizzi E, et al. Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine. Hum Vaccin Immunother [Internet]. 2019 Jan 2 [cited 2022 Oct 13];15(1):141-5. Doi: https://doi.org/10.1080/21645515.2018.1514227 PMid:30261146 PMCid:PMC6363163

Lacey CJN, Thompson HSG, Monteiro EF, O'Neill T, Davies ML, Holding FP, et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis [Internet]. 1999 [cited 2022 Oct 13];179(3):612-8. Doi: https://doi.org/10.1086/314616 PMid:9952367

Cervarix HPV Vaccination Series | The Embryo Project Encyclopedia [Internet]. [cited 2022 Oct 13]. Available from: https://embryo.asu.edu/pages/cervarix-hpv-vaccination-series

Yang A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. J Biomed Sci [Internet]. 2016 Nov 4 [cited 2022 Oct 13];23(1):1-19. Doi: https://doi.org/10.1186/s12929-016-0293-9 PMid:27809842 PMCid:PMC5096309

Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J, et al. Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives. Front Cell Infect Microbiol. 2022 Jul 4;12:901. Doi: https://doi.org/10.3389/fcimb.2022.909223 PMid:35860379 PMCid:PMC9289603

HPV and Cancer - NCI [Internet]. [cited 2022 Oct 13]. Available from: https://www.cancer.gov/about-cancer/causes-preven-tion/risk/infectious-agents/hpv-and-cancer#related-research

Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med [Internet]. 2002 Nov 21 [cited 2022 Nov 27];347(21):1645-51. Doi: https://doi.org/10.1056/NEJMoa020586 PMid:12444178

Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer [Internet]. 2006 Oct [cited 2022 Nov 27];6(10):753. Doi: https://doi.org/10.1038/nrc1973 PMid:16990853 PMCid:PMC3181152

Berkhof J, Bogaards JA. Vaccination against human papillomavirus types 16 and 18: the impact on cervical cancer. http://dx.doi.org/102217/fon10150 [Internet]. 2010 Dec 13 [cited 2022 Nov 27]; Doi: https://doi.org/10.2217/fon.10.150 PMid:21142854